M J Redondo1, S F A Grant2,3, A Davis4, C Greenbaum4. 1. Department of Pediatrics, Section of Diabetes and Endocrinology, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA. 2. Divisions of Human Genetics and Endocrinology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA. 3. Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 4. Diabetes Clinical Research Program, Benaroya Research Institute, Seattle, WA, USA.
Abstract
AIMS: To test the hypothesis that non-obese individuals with childhood-onset Type 1 diabetes and the rs7903146 TT genotype would be less likely to have high-risk human leukocyte antigen (HLA) genotypes and alleles. METHODS: We studied a cohort of 105 non-obese participants in the T1D Exchange Biobank Residual Insulin Study who had childhood-onset Type 1 diabetes [mean (sd) age at onset and recruitment, respectively, 9.9 (4.15) and 14.4 (4.13) years; 84.8% non-Hispanic white]. We analysed islet autoantibodies (glutamic acid decarboxylase 65, islet cell autoantigen 512/islet antigen-2 and zinc transporter 8), non-fasting random C-peptide levels, HLA type and TCF7L2 single nucleotide polymorphism rs7903146 in this cohort. RESULTS: None of the 13 individuals with the rs7903146 TT genotype carried the highest Type 1 diabetes risk HLA genotype, i.e. DRB1*03:01/DR4 (DRB1*0401, *04:05 or *04:02), compared with 29.4% (27/92) of those without it (P=0.023). The DRB1*03:01 allele was present in 15.4% (2/13) of individuals with the single nucleotide polymorphism, compared with 59.8% (55/92) of those without it (P=0.003). Analyses restricted to autoantibody-positive individuals (n=80) yielded similar results. The HLA DRB1*15:01 allele, which affords dominant protection against Type 1 diabetes, was found in one participant, who had multiple islet autoantibodies and carried the rs7903146 TT genotype. CONCLUSIONS: These findings further support the hypothesis that TCF7L2 gene variation contributes to diabetogenesis in a subset of young people with Type 1 diabetes, opening possible new pathways for therapy and prevention.
AIMS: To test the hypothesis that non-obese individuals with childhood-onset Type 1 diabetes and the rs7903146 TT genotype would be less likely to have high-risk human leukocyte antigen (HLA) genotypes and alleles. METHODS: We studied a cohort of 105 non-obeseparticipants in the T1D Exchange Biobank Residual Insulin Study who had childhood-onset Type 1 diabetes [mean (sd) age at onset and recruitment, respectively, 9.9 (4.15) and 14.4 (4.13) years; 84.8% non-Hispanic white]. We analysed islet autoantibodies (glutamic acid decarboxylase 65, islet cell autoantigen 512/islet antigen-2 and zinc transporter 8), non-fasting random C-peptide levels, HLA type and TCF7L2 single nucleotide polymorphism rs7903146 in this cohort. RESULTS: None of the 13 individuals with the rs7903146 TT genotype carried the highest Type 1 diabetes risk HLA genotype, i.e. DRB1*03:01/DR4 (DRB1*0401, *04:05 or *04:02), compared with 29.4% (27/92) of those without it (P=0.023). The DRB1*03:01 allele was present in 15.4% (2/13) of individuals with the single nucleotide polymorphism, compared with 59.8% (55/92) of those without it (P=0.003). Analyses restricted to autoantibody-positive individuals (n=80) yielded similar results. The HLA DRB1*15:01 allele, which affords dominant protection against Type 1 diabetes, was found in one participant, who had multiple islet autoantibodies and carried the rs7903146 TT genotype. CONCLUSIONS: These findings further support the hypothesis that TCF7L2 gene variation contributes to diabetogenesis in a subset of young people with Type 1 diabetes, opening possible new pathways for therapy and prevention.
Authors: Maria J Redondo; Carmella Evans-Molina; Andrea K Steck; Mark A Atkinson; Jay Sosenko Journal: Diabetes Care Date: 2019-06-04 Impact factor: 19.112
Authors: Maria J Redondo; Andrea K Steck; Jay Sosenko; Mark Anderson; Peter Antinozzi; Aaron Michels; John M Wentworth; Mark A Atkinson; Alberto Pugliese; Susan Geyer Journal: Diabetes Care Date: 2018-10-01 Impact factor: 19.112
Authors: Carmella Evans-Molina; Emily K Sims; Linda A DiMeglio; Heba M Ismail; Andrea K Steck; Jerry P Palmer; Jeffrey P Krischer; Susan Geyer; Ping Xu; Jay M Sosenko Journal: JCI Insight Date: 2018-08-09
Authors: Pia Leete; Roberto Mallone; Sarah J Richardson; Jay M Sosenko; Maria J Redondo; Carmella Evans-Molina Journal: Curr Diab Rep Date: 2018-09-26 Impact factor: 4.810
Authors: Maria J Redondo; Brandon M Nathan; Laura M Jacobsen; Emily Sims; Laura E Bocchino; Alberto Pugliese; Desmond A Schatz; Mark A Atkinson; Jay Skyler; Jerry Palmer; Susan Geyer; Jay M Sosenko Journal: Diabetologia Date: 2021-01-26 Impact factor: 10.122
Authors: Maria J Redondo; Megan V Warnock; Ingrid M Libman; Laura E Bocchino; David Cuthbertson; Susan Geyer; Alberto Pugliese; Andrea K Steck; Carmella Evans-Molina; Dorothy Becker; Jay M Sosenko; Fida Bacha Journal: Diabetes Care Date: 2021-07-29 Impact factor: 17.152
Authors: Maria J Redondo; Susan Geyer; Andrea K Steck; Jay Sosenko; Mark Anderson; Peter Antinozzi; Aaron Michels; John Wentworth; Ping Xu; Alberto Pugliese Journal: Diabetes Care Date: 2017-10-12 Impact factor: 19.112
Authors: Rajashree Mishra; Alessandra Chesi; Diana L Cousminer; Mohammad I Hawa; Jonathan P Bradfield; Kenyaita M Hodge; Vanessa C Guy; Hakon Hakonarson; Didac Mauricio; Nanette C Schloot; Knud B Yderstræde; Benjamin F Voight; Stanley Schwartz; Bernhard O Boehm; Richard David Leslie; Struan F A Grant Journal: BMC Med Date: 2017-04-25 Impact factor: 8.775